Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
77.4 EUR | -1.84% |
|
-2.11% | -17.12% |
06-24 | BioNTech, Duality Biologics Receive FDA Fast-Track Designation for Prostate Cancer Drug | MT |
06-24 | BioNTech Cancer Treatment Gets US FDA Fast Track Designation | DJ |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Immunotherapy Technologies
100.0
%
| 18,193 | 100.0 % | 4,129 | 100.0 % | -77.31% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
78.8
%
| 13,358 | 73.4 % | 3,255 | 78.8 % | -75.63% |
Germany
12.6
%
| 3,186 | 17.5 % | 522 | 12.6 % | -83.62% |
International
8.8
%
| 1,488 | 8.2 % | 362 | 8.8 % | -75.70% |
Turkey
-0.2
%
| 162 | 0.9 % | -10 | -0.2 % | -106.09% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ugur Sahin
CEO | Chief Executive Officer | 58 | 08-06-01 |
Özlem Türeci
FOU | Founder | 57 | 08-06-01 |
Jens Holstein
DFI | Director of Finance/CFO | 60 | 21-06-30 |
Sierk Poetting
COO | Chief Operating Officer | 51 | 14-08-31 |
Sean Marett
COO | Chief Operating Officer | 59 | - |
Michael Horowicz
IRC | Investor Relations Contact | - | - |
James Ryan
LAW | General Counsel | - | 18-06-30 |
Ryan Richardson
PRN | Corporate Officer/Principal | 57 | 18-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Rudolf Staudigl
BRD | Director/Board Member | 70 | 21-12-31 |
Director/Board Member | 67 | 08-06-01 | |
Helmut Jeggle
CHM | Chairman | 53 | 08-06-01 |
Director/Board Member | 63 | 17-12-31 | |
Director/Board Member | - | 23-05-24 | |
Anja Morawietz
BRD | Director/Board Member | 47 | 21-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 248,552,200 | 214,949,219 ( 86.48 %) | 10,826,465 ( 4.356 %) | 86.48 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
AUTOLUS THERAPEUTICS PLC 20.06% | 33,333,333 | 20.06% | 139,666,665 $ |
RYVU THERAPEUTICS S.A. 8.29% | 1,917,437 | 8.29% | 26,299,623 $ |
Company contact information
![address BioNTech SE(22UA)](https://cdn.zonebourse.com/static/address/112014263.png)
Sector
Sales per region
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.49% | 122B | |
+21.73% | 116B | |
+22.18% | 27.03B | |
-16.89% | 16.43B | |
-18.81% | 15.91B | |
-44.74% | 15.6B | |
+62.72% | 14.94B | |
+3.09% | 13.59B | |
+122.59% | 11.24B |
- Stock Market
- Equities
- BNTX Stock
- 22UA Stock
- Company BioNTech SE